Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 935 record(s)

Req # A-2021-000021

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116090-508.

Organization: Health Canada

9 page(s)
December 2021

Req # A-2021-000073

Adverse Drug Reactions (ADRs) for Mesalazine. Report numbers: E2B_03706888, E2B_03703577, E2B_03690817, E2B_03650148, E2B_03703572, 000934984, 000934900. ADRs for Vyvanse. Report numbers: 000933539, 000934356, 000934242, 000933957. ADR for Antihemophilic factor (recombinant). Report number: E2B_03664870. ADRs for C1 Esterase Inhibitor (Human). Report numbers: E2B_03673052, E2B_03667877, E2B_03698698. ADR for Gammagard Liquid. Report number: 000933632.

Organization: Health Canada

116 page(s)
December 2021

Req # A-2021-000177

Adverse Drug Reaction (ADR). Report number: E2B_03769938.

Organization: Health Canada

11 page(s)
December 2021

Req # A-2021-000187

Adverse Drug Reactions (ADRs). Report numbers: E2B_00767615, E2B_02625820, E2B_03239333, E2B_03294549, E2B_03344059, E2B_03353109, E2B_02247251, E2B_03317883, E2B_02625820, E2B_02676622.

Organization: Health Canada

466 page(s)
December 2021

Req # A-2021-000420

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 21-075019-732.

Organization: Health Canada

6 page(s)
December 2021

Req # A-2021-000479

Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 20-116936-246.

Organization: Health Canada

15 page(s)
December 2021

Req # A-2021-000506

Adverse Drug Reaction (ADR) TERIFLUNOMIDE. Report number: E2B_03519847.

Organization: Health Canada

8 page(s)
December 2021

Req # A-2021-000535

Adverse Drug Reactions (ADRs) for CLOPIDOGREL BISULFATE. Report numbers: E2B_03388107, E2B_03388434.

Organization: Health Canada

21 page(s)
December 2021

Req # A-2021-000557

Adverse Drug Reactions (ADRs) for TRIAMCINOLONE ACETONIDE. Report numbers: E2B_03413307, E2B_03432341, E2B_03310509, E2B_03518327.

Organization: Health Canada

59 page(s)
December 2021

Req # A-2021-000564

Adverse Drug Reactions (ADRs) for ACEBUTOLOL HYDROCHLORIDE. Report numbers: 000929730, E2B_03505032, E2B_03371322, E2B_03498962, E2B_03501946, E2B_03482477.

Organization: Health Canada

158 page(s)
December 2021
Date modified: